natgillin/translations-raw huggingface dataset:
The full EPAR for Evarrest can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Evarresti kohta on ameti veebilehel: : ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A risk management plan has been developed to ensure that Evarrest is used as safely as possible.
Töötati välja riskijuhtimisstrateegia, et tagada Evarresti võimalikult ohutu kasutamine.
Other information about Evarrest
Muu teave Evarresti kohta
What measures are being taken to ensure the safe and effective use of Evarrest?
Mis meetmeid võetakse, et tagada Evarresti ohutu ja efektiivne kasutamine?
It should only be used in a single layer with an overlap of 1 to 2 cm on the surrounding non-bleeding tissue.
Seda tohib kasutada ainult ühe kihina, mis ulatub 1−2 cm ümbritsevale mitteveritsevale koele.
Evarrest must not be used to repair the walls of large blood vessels, must not be applied to the inside of blood vessels and must not be used in closed spaces (such as openings in bones).
Evarresti ei tohi kasutada suurte veresoonte seinte parandamiseks, seda ei tohi paigutada veresoonte siseküljele ega kasutada kinnistes kohtades (avaused luudes).
What is Evarrest and what is it used for?
Mis on Evarrest ja milleks seda kasutatakse?
This is a summary of the European public assessment report (EPAR) for Evarrest.
See on ravimi Evarrest Euroopa avaliku hindamisaruande kokkuvõte.
The CHMP concluded that the benefits of Evarrest outweigh its risks and recommended that it be granted marketing authorisation.
Inimravimite komitee järeldas, et Evarresti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Evarrest is made of absorbable material that can be left in the patients after surgery.
Evarrest on valmistatud imenduvast materjalist, mille võib jätta pärast operatsiooni patsiendi sisse.
Why is Evarrest approved?
Miks Evarrest heaks kiideti?
Evarrest should therefore only be used when standard methods for controlling bleeding are not sufficient.
Seetõttu tohib Evarresti kasutada ainult siis, kui verejooksu peatamise standardmeetodid ei ole piisavad.
Evarrest should only be used by experienced surgeons who will judge the amount to use based on the size and location of the bleeding area.
Evarresti tohivad kasutada ainult kogenud kirurgid, kes otsustavad lapi suuruse üle veritseva piirkonna suuruse ja asukoha alusel.
What are the risks associated with Evarrest?
Mis riskid Evarrestiga kaasnevad?
It is not intended to provide practical advice on how to use Evarrest.
Hindamisaruandes ei anta Evarresti kasutamise praktilisi nõuandeid.
The active substances in Evarrest, fibrinogen and thrombin, are proteins extracted from the blood, which are involved in the natural clotting process.
Evarresti toimeained fibrinogeen ja trombiin on verest eraldatud valgud, mis osalevad loomulikus verehüübimisprotsessis.
How is Evarrest used?
Kuidas Evarresti kasutatakse?
The complications that arise in patients being treated with Evarrest are generally related to the surgical procedure and the underlying conditions, and include post-surgery bleeding and increased fibrinogen levels in the blood.
Evarrestiga ravitud patsientidel tekkivad tüsistused on tavaliselt seotud kirurgilise protseduuri ja kaasnevate seisunditega ning nende hulka kuuluvad operatsioonijärgne verejooks ja suurenenud fibrinogeenisisaldus veres.
Thrombin works by cutting fibrinogen up into smaller units called fibrin, which then stick together to form clots.
Trombiini toimel lõhustub fibrinogeen väiksemateks osadeks, mida nimetatakse fibriiniks.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Evarrest, including the appropriate precautions to be followed by healthcare professionals and patients.
Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Evarresti ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
The clots enable the patch to stick more firmly to the tissue thereby helping to stop the bleeding.
Hüübed võimaldavad lapil paremini koe külge kleepuda, aidates verejooksu peatada.
For practical information about using Evarrest, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate Evarresti kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
98% of the patients in the Evarrest group (59 out of 60) had their bleeding stopped within 4 minutes (with no recurrence of bleeding during a 6-minute observation period) compared with 53% of patients in the Surgicel group (16 out of 30).
98%-l patsientidest Evarresti rühmas (59 patsienti 60st) peatus verejooks 4 minutiga (veritsus ei kordunud 6-minutise jälgimisperioodi jooksul) võrreldes 53%-ga Surgiceli rühma patsientidest (16 patsienti 30st).
Two studies compared Evarrest with commonly used surgical techniques considered to be standard care.
Kahes uuringus võrreldi Evarresti tavaliselt kasutatavate kirurgiliste meetoditega (standardravi).
For more information about treatment with Evarrest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Evarrestiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Evarrest is a surgical product used in adults to help stop bleeding during surgery when standard methods for controlling bleeding are not sufficient.
Evarrest on kirurgiline vahend, mida kasutatakse operatsiooni ajal verejooksu peatamiseks täiskasvanud patsientidel, kui verejooksu peatamise standardmeetodid ei ole piisavad.
The complications seen in studies with Evarrest were generally related the surgical procedure and the underlying conditions although there were cases of re-bleeding from the sites where Evarrest patches were used.
Uuringutes Evarrestiga täheldatud tüsistused olid üldiselt seotud kirurgilise protseduuri ja kaasnevate seisunditega, kuigi esines ka verejooksu kohtadest, kus Evarresti kasutati.
For the full list of all side effects reported with Evarrest, see the package leaflet.
Evarresti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
When an Evarrest patch is applied to a bleeding area during surgery, the moisture causes the active substances to react together, leading to the rapid formation of clots.
Kui Evarrest kantakse veritsevale piirkonnale operatsiooni ajal, põhjustab niiskus toimeainete omavahelist reageerimist, mis kiirendab hüüvete teket.
Evarrest has been shown in studies to be effective in helping to stop bleeding during surgeries, with most patients having their bleeding stopped within 4 minutes.
Uuringutes on näidatud, et Evarrest on operatsiooniaegse verejooksu peatamisel efektiivne: enamikul patsientidest peatub verejooks 4 minuti jooksul.
Similar results were seen in a study in patients undergoing liver surgery: 83% of patients in the Evarrest group (33 out of 40) had their bleeding stopped within 4 minutes compared with 30% of the standard care group (13 out of 44).
Sarnaseid tulemusi täheldati uuringus patsientidel, kellele tehti maksaoperatsioon: 83%-l patsientidest Evarresti rühmas (33 patsienti 40st) peatus verejooks 4 minutiga võrreldes 30%-ga standardravi rühmas (13 patsienti 44st).
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Evarrest was shown to be effective when used to stop bleeding in surgery and the product could be a suitable alternative to other products and techniques.
Inimravimite komitee märkis, et on tõendatud Evarresti efektiivsus verejooksu peatamisel kirurgiliste protseduuride käigus ning et see on olemasolevate vahendite ja meetodite sobiv alternatiiv.
One study compared Evarrest with another product, Surgicel, in patients undergoing abdominal, thoracic and pelvic surgeries.
Ühes uuringus võrreldi Evarresti teise vahendi Surgiceliga patsientidel, kellele tehti kõhu-, rindkere- või vaagnaoperatsioon.
In a study in patients undergoing abdominal, thoracic and pelvic surgeries, 84% of patients in the Evarrest group had their bleeding stopped within 4 minutes (50 out of 59) compared with 31% (10 out of 32) in the standard care group.
Uuringus patsientidel, kellele tehti kõhu-, rindkere- või vaagnaoperatsioon, peatus 84%-l patsientidest Evarresti rühmas (50 patsienti 59st) verejooks 4 minutiga võrreldes 31%-ga standardravi patsientidest (10 patsienti 32st).
During surgery, the patches are cut to shape and size and used to seal off the bleeding area.
Operatsiooni ajal lõigatakse sellest sobiva kuju ja suurusega tükid, millega kaetatakse veritsev piirkond.
What benefits of Evarrest have been shown in studies?
Milles seisneb uuringute põhjal Evarresti kasulikkus?
How does Evarrest work?
Kuidas Evarrest toimib?
It is made of absorbable material coated on one side with two active substances, fibrinogen and thrombin, and is available as 10.2 cm x 10.2 cm patches.
Evarrest koosneb imenduvast materjalist, mis on ühelt poolt kaetud kahe toimeaine, fibrinogeeni ja trombiiniga.
Packaging Content Package sizeWithdrawal period
Sisaldus Pakendi suurus
MA (EU) Number (Invented) name
(Väljamõel dud) nimetus
Solution for injection
Kontsentraat infusioonilahuse valmistamiseks
Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Ravimiamet vaatab kogu võimaliku uue teabe igal aastal läbi ja vajaduse korral uuendab käesolevat kokkuvõtet.
Pixuvri can be given for up to six cycles.
Pixuvrit võib anda kuni kuue tsüklina.
The side effects of the medicine were considered to be short term and manageable.
Ravimi kõrvalnähte peeti lühiajaliseks ja kontrollitavaks.
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Pixuvri on 10 May 2012.
Euroopa Komisjon andis Pixuvri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. mail 2012.
The full EPAR for Pixuvri can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Euroopa avaliku hindamisaruande täistekst Pixuvri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The main measure of effectiveness was the number patients who had a complete response to treatment.
Peamine tulemusnäitaja oli täieliku ravivastusega patsientide arv.
In addition, patients treated with Pixuvri lived for longer without their disease getting worse.
Peale selle elasid Pixuvriga ravitud patsiendid kauem, ilma et nende haigus oleks süvenenud.
The recommended dose is 50 mg/m2 given as an infusion into a vein over at least 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Soovitatav annus on 50 mg/m2 veenisisese infusioonina vähemalt 60 minuti jooksul 28-päevase ravitsükli 1., 8. ja 15. päeval.
This means that the cancer cells in non-Hodgkin's B cell lymphoma cannot divide and eventually die.
See tähendab, et B-rakulise mitte-Hodgkini lümfoomi vähirakud ei saa jaguneda ja lõpuks hävivad.
This means that there is more evidence to come about the medicine, in particular its benefits in patients who have previously been treated with rituximab.
See tähendab, et ravimi kohta oodatakse veel andmeid, eelkõige selle kasulikkuse kohta patsientidel, keda on varem ravitud rituksimaabiga.
The CHMP concluded that the benefits of Pixuvri are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee järeldas, et Pixuvri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The dose of Pixuvri is based on the patient's body surface area (calculated using the patient's height and weight).
Pixuvri annus määratakse patsiendi kehapindala alusel (arvutatakse pikkuse ja kaalu järgi).
The most common side effects with Pixuvri (seen in more than 1 patient in 10) are neutropenia, leucopenia and lymphopenia (low levels of different types of white blood cells), thrombocytopenia (low levels of platelets in the blood), anaemia (low levels of red blood cells), nausea (feeling sick), vomiting, skin discolouration, hair loss, chromaturia (abnormal colouration of the urine) and asthenia (weakness).
Pixuvri kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10-st) on neutropeenia, leukopeenia ja lümfopeenia (eri tüüpi valgeliblede vähesus), trombotsütopeenia (vereliistakute vähesus), aneemia (punaliblede vähesus), iiveldus, oksendamine, naha värvimuutus, juuste väljalangemine, kromatuuria (uriini ebanormaalne värvus) ja asteenia (nõrkus).
It must not be used in patients with severe liver problems and in patients whose bone marrow produces abnormally low levels of blood cells.
Seda ravimit ei tohi kasutada ka patsiendid, kellel on tõsised maksaprobleemid, ja patsiendid, kelle luuüdi toodab ebanormaalselt vähe vererakke.
Pixuvri has been given ‘conditional approval'.
Pixuvri müügiluba anti tingimusliku heakskiidu alusel.
Patients were given either six cycles of Pixuvri or another approved anticancer medicine chosen by their doctor.
Patsientidele anti 6 tsüklit Pixuvrit või muud arsti valitud heakskiidetud vähiravimit.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pixuvri.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
EPAR summary for the public pixantrone
Kokkuvõte üldsusele piksantroon
Pixuvri is a medicine that contains the active substance pixantrone.
Pixuvri on ravim, mis sisaldab toimeainena piksantrooni.
In patients who develop side effects or who have very low blood levels of neutrophils (a type of white blood cell that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Patsientidel, kellel tekivad kõrvalnähud või kellel on veres vähe neutrofiile (teatud infektsioonivastaseid valgeliblesid) ja trombotsüüte (vereliistakuid ehk hüübimist soodustavaid vererakke), võib olla vaja annust vähendada või tuleb ravi edasi lükata.
For more information about treatment with Pixuvri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Pixuvriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Patients receiving Pixuvri must not be given vaccines containing attenuated (weakened live) viruses.
Pixuvrit kasutavatele patsientidele ei tohi manustada nõrgestatud (nõrku, kuid elusaid) viirusi sisaldavaid vaktsiine.
Other information about Pixuvri
Muu teave Pixuvri kohta
The company that makes Pixuvri will carry out a study to further investigate the effects of using Pixuvri in patients who had received prior treatment with rituximab.
Ettevõte, mis toodab Pixuvrit, korraldab uuringu Pixuvri toimete kohta patsientidel, keda on varem ravitud rituksimaabiga.
This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells.
See on lümfikoe (immuunsüsteemi osa) vähk, mis kahjustab teatud valgeliblesid B-lümfotsüüte ehk B-rakke.
What information is still awaited for Pixuvri?
Mis teavet Pixuvri kohta veel oodatakse?
Why has Pixuvri been approved?
Miks Pixuvri heaks kiideti?
Pixuvri must not be used in patients who are hypersensitive (allergic) to pixantrone or any of the other ingredients.
Pixuvrit ei tohi kasutada patsiendid, kes on piksantrooni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin's B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment.
Pixuvrit võrreldi teiste keemiaravi ravimitega ühes põhiuuringus, milles osales 140 agressiivse B-rakulise mitte-Hodgkini lümfoomiga täiskasvanut, kes said enne vähemalt kahte muud ravimit ja kelle vähk oli retsidiveerunud või ei andnud muu ravi piisavat ravivastust.
It is available as a powder that is made up into a solution for infusion (a drip into a vein).
Seda turustatakse pulbrina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
However, the Committee noted that more data were needed on the benefits of Pixuvri in patients who have received previous treatment with rituximab (another medicine commonly used to treat lymphoma).
Siiski tegi inimravimite komitee märkuse, et Pixuvri kasulikkuse kohta on vaja rohkem andmeid patsientidel, keda on varem ravitud rituksimaabiga (teine lümfoomi ravis sageli kasutatav ravim).
For the full list of all side effects reported with Pixuvri, see the package leaflet.
Pixuvri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin's B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients).
Pixuvriga tekkis täielik ravivastus 20%-l patsientidest (14 patsienti 70-st) võrreldes 5,7%-ga muud ravi saanud patsientidest (4 patsienti 70-st).
This is a summary of the European public assessment report (EPAR) for Pixuvri.
See on ravimi Pixuvri Euroopa avaliku hindamisaruande kokkuvõte.
The CHMP also considered the seriousness of the disease and the lack of suitable alternative treatments for patients whose non-Hodgkin's B cell lymphoma has come back or has not responded to other chemotherapy treatments.
Inimravimite komitee võttis arvesse ka haiguse raskusastet ja sobivate alternatiivsete ravimite puudumist patsientide jaoks, kelle agressiivne B-rakuline mitte-Hodgkini lümfoom retsidiveerus või kes ei saavutanud muude keemiaravi ravimitega piisavat ravivastust.
What is Pixuvri?
Mis on Pixuvri?
The active substance in Pixuvri, pixantrone, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anthracyclines'.
Pixuvri toimeaine piksantroon on antratsükliinide (raku normaalset ainevahetust pärssivad ained) hulka kuuluv tsütotoksiline ravim (poolduvaid rakke, näiteks vähirakke hävitav ravim).
Pixuvri must be given by a doctor who has experience in the use of anticancer medicines and who has access to facilities for monitoring the patient.
Pixuvrit tohib määrata üksnes vähiravis kogenud arst, kel on võimalik patsiendi seisukorda jälgida.
Pixuvri is used when the lymphoma is aggressive and has come back or has not responded to other chemotherapy treatments (medicines to treat cancer).
Pixuvrit kasutatakse juhul, kui tegemist on agressiivse retsidiveerunud lümfoomiga või kui muu keemiaraviga (vähi ravimravi) ei ole tekkinud piisavat ravivastust.
What is the risk associated with Pixuvri?
Mis riskid Pixuvriga kaasnevad?
Pixuvri is used to treat adult patients with non-Hodgkin's B cell lymphoma.
Pixuvrit kasutatakse B-rakulise mitte-Hodgkini lümfoomiga täiskasvanud patsientide raviks.
The effects of Pixuvri were first tested in experimental models before being studied in humans.
Enne inimuuringuid kontrolliti Pixuvri toimet muude katsetega.
What is Pixuvri used for?
Milleks Pixuvrit kasutatakse?
The CHMP concluded that patients with aggressive non-Hodgkin's B cell lymphoma had a better response to treatment with Pixuvri than other cancer treatments.
Inimravimite komitee jõudis järeldusele, et Pixuvrit kasutavate agressiivse B-rakulise mitte-Hodgkini lümfoomiga patsientide ravivastus oli parem kui teisi ravimeid kasutanud patsientidel.
How is Pixuvri used?
Kuidas Pixuvrit kasutatakse?
How does Pixuvri work?
Kuidas Pixuvri toimib?
How has Pixuvri been studied?
Kuidas Pixuvrit uuriti?
What benefit has Pixuvri shown during the studies?
Milles seisneb uuringute põhjal Pixuvri kasulikkus?
The medicine can only be obtained with a prescription.
Pixuvri on retseptiravim.
The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte ravimi Pemetrexed medac kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A risk management plan has been developed to ensure that Pemetrexed medac is used as safely as possible.
Töötati välja riskijuhtimiskava, et tagada ravimi Pemetrexed medac võimalikult ohutu kasutamine.
What measures are being taken to ensure the safe and effective use of Pemetrexed medac?
Mis meetmed võetakse, et tagada ravimi Pemetrexed medac ohutu ja efektiivne kasutamine?
The Committee recommended that Pemetrexed medac be approved for use in the EU.
Komitee soovitas ravimi Pemetrexed medac kasutamise Euroopa Liidus heaks kiita.
No additional studies were needed as Pemetrexed medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Lisauuringuid ei olnud vaja, sest Pemetrexed medac on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed medac.
Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb ravimiga Pemetrexed medac toimuva ravi ajal süstida vitamiini B12.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed medac, including the appropriate precautions to be followed by healthcare professionals and patients.
Selle alusel lisati ravimi Pemetrexed medac omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed medac has been shown to be comparable to Alimta.
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pemetrexed medac sarnane toime ravimiga Alimta.
Because Pemetrexed medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Et Pemetrexed medac on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
This is a summary of the European public assessment report (EPAR) for Pemetrexed medac.
See on ravimi Pemetrexed medac Euroopa avaliku hindamisaruande kokkuvõte.
This means that Pemetrexed medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
See tähendab, et Pemetrexed medac on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
Pemetrexed medac is a cancer medicine used to treat two types of lung cancer:
Pemetrexed medac on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
• advanced non-small-cell lung cancer of the kind known as ‘non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
• kaugelearenenud mitteväikerakk-kopsuvähi muu kui lamerakuline vorm, kusjuures ravimit kasutatakse varem ravimata patsientidel koos tsisplatiiniga ja ainsa ravimina patsientidel, kes on varem saanud vähiravi.
For practical information about using Pemetrexed medac, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate ravimi Pemetrexed medac kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.